Form 4: VolitionRx CSO's Tax Withholding on RSU Settlement

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, reported a disposition of 5,568 common shares for tax withholding related to restricted stock unit settlement.

Summary

• Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd (VNRX), reported a transaction on September 28, 2025.
• The transaction involved the disposition of 5,568 shares of common stock.
• This disposition was for the purpose of satisfying tax withholding obligations upon the settlement of 12,375 restricted stock units.
• No shares were sold by the reporting person or VolitionRx in this transaction.
• Following the transaction, direct beneficial ownership stands at 398,939 shares.
• Indirect beneficial ownership includes 55,000 shares held by a spouse and 38,113 shares held by Borlaug Limited, an entity where the reporting person is a controlling director.

Sentiment

Score: 5

Explanation: The filing reports a routine tax withholding transaction related to RSU vesting, which is a standard compensation event and does not indicate a significant positive or negative operational or financial development.

Positives

• The settlement of 12,375 restricted stock units indicates the vesting of compensation for the Chief Scientific Officer, reflecting a standard component of executive remuneration.

Negatives

• The disposition of 5,568 shares, even for tax purposes, results in a reduction of the reporting person's direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not indicate a material change in company fundamentals or strategy.
• Chief Scientific Officer: The transaction reflects the receipt of vested compensation in the form of restricted stock units, with a portion withheld for tax obligations.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding transaction for the Chief Scientific Officer upon the vesting of restricted stock units. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a standard compensation event and does not reflect a discretionary sale by the insider.

Keywords

VolitionRx, VNRX, Form 4, Insider Transaction, Restricted Stock Units, Tax Withholding, Jacob Vincent Micallef, Chief Scientific Officer